GKCAS 2024 Annual Symposium

Lenexa, KS US
January 27, 2024

The Greater Kansas City Allergy Society's Annual Symposium brings together providers, nurses, fellows and interested students and residents of the greater Kansas City area to provide education on the latest relevant topics in allergy and clinical immunology. The symposium provides didactic lectures by renowned experts on relevant topics. Topics to be covered this year are nut allergy, respiratory viral infections and atopic disease, Hypereosinophilic Syndrome and eosinophilic gastrointestinal diseases, and treatment of severe asthma. A business meeting will also be conducted to discuss the activities of the GKCAS over the last year.


This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the American College of Allergy, Asthma & Immunology (ACAAI) and the Greater Kansas City Allergy Society (GKCAS).  The American College of Allergy, Asthma and Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 4 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The American College of Allergy, Asthma & Immunology (ACAAI) is a provider, approved by the California Board of Registered Nursing, Provider Number CEP17239, for 4 contact hours. 

Commercial Support
This activity is supported in part by independent medical education grants from DBV Technologies, Genentech, and Grifols.

Target Audience

Allied Health Professionals
Fellows and Residents

Learning Objectives

At the conclusion of this Activity learners should be able to…
1. Evaluate the latest advancements in food allergy management.
2. Implement a food immunotherapy program as an option for patients.
3. Perform a thorough and updated immune and genetic evaluation for inborn errors of immunity. 
4. Appropriately manage immune dysregulation in those with inborn errors of immunity.
5. Recommend the optimal biologic for a relevant refractory atopic condition. 

Additional information

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months.

Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients. The ACCME does not consider providers of clinical service directly to patients to be ineligible companies. Examples of ineligible companies include:

•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers

For more information, visit www.accme.org.

All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.

Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All relevant financial relationships with ineligible companies have been mitigated.

Course summary
Available credit: 
  • 4.00 AMA PRA Category 1 Credit™
  • 4.00 Attendance
  • 4.00 CBRN
Course opens: 
Course expires: 
Event starts: 
01/27/2024 - 8:30am CST
Event ends: 
01/27/2024 - 2:00pm CST

GKCAS Annual Symposium
January 27, 2024
Hyatt Place Kansas City/Lenexa City Center

8:30-9:00 am Registration and Breakfast while visiting Vendor Exhibits

8:50 am Welcome and Introduction

9:00-11:00 am "A Hard Nut to Crack: Unraveling Novel Approaches in Food Allergy Treatment"
Dr. Andrew Bird

10:00am-11:00am “Inborn errors of immunity – the prime time, the needs, the future”.
Dr. Joao Pedro Lopes

11:00am-12:00pm “Asthma Biologics: New Therapeutic Landscape”
Dr. Rohit Katial

12:00pm-12:30pm Lunch

12:30pm-1:30 pm “Genetics in Antibody Deficiency: what have we learned?”
Dr. Charlotte Cunningham-Rundles

1:30pm – 2:00 pm Final Announcements and Adjournment

Hyatt Place Kansas City Lenexa City Center
8741 Ryckkert Street
Lenexa, KS 66219
United States

All relevant financial relationships with ineligible companies have been mitigated.

Will Lavery, MD, Planner
Speaker: GSK

Rohit Katial MD, Speaker
Speaker: AstraZeneca

J. Andrew Bird, MD, Speaker
Speaker: DBV
Consultant: DBV, Novartis, Genentech
Researcher: DBV, Genentech, Novartis, Regeneron, Siolta

Charlotte Cunningham-Rundles MD PhD, Speaker
Advisor: Pharming, X4
Speaker: Grifols
Consultant: Otsuka
Researcher: Sanofi, Jounce

The following have no relevant financial relationships with ineligible companies to disclose:

Brynn Everist, MD, Planner

Joao Pedro Matias Lopes, MD, Speaker

Aarti Pandya MD, Planner 

Jeehyun Rha MD, Planner

Kristen Welborn APRN, Planner

Available Credit

  • 4.00 AMA PRA Category 1 Credit™
  • 4.00 Attendance
  • 4.00 CBRN
Please login or create an account to take this course.